Downregulation, Blood Type, Paternal Lineage, and Genetic Variants in Ovarian Cancer: A Call for Tumor Suppressor Genes Effectiveness

2019 ◽  
Author(s):  
Clarence St.Hilaire ◽  
Candida Dhanaraj ◽  
Satyajit Patra ◽  
Sahana Salins
Keyword(s):  
Ovarian Cancer ◽  
Tumor Suppressor ◽  
Genetic Variants ◽  
Tumor Suppressor Genes ◽  
Blood Type ◽  
Suppressor Genes ◽  
Paternal Lineage

scholarly journals Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer

2013 ◽  
Vol 35 (3) ◽  
pp. 546-553 ◽  
Author(s):  
Pradeep S. Tanwar ◽  
Gayatry Mohapatra ◽  
Sarah Chiang ◽  
David A. Engler ◽  
LiHua Zhang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Tumor Suppressor ◽  
Tumor Suppressor Genes ◽  
Ovarian Surface Epithelium ◽  
Surface Epithelium ◽  
Serous Ovarian Cancer ◽  
Suppressor Genes ◽  
Ovarian Surface

scholarly journals Expression analysis of the MCPH1/BRIT1 and BRCA1 tumor suppressor genes and telomerase splice variants in epithelial ovarian cancer

Gene ◽  
2018 ◽  
Vol 672 ◽  
pp. 34-44 ◽  
Author(s):  
Rawiah Alsiary ◽  
Samantha C. Brownhill ◽  
Anke Brüning-Richardson ◽  
Richard Hutson ◽  
Nicholas Griffin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Tumor Suppressor ◽  
Epithelial Ovarian Cancer ◽  
Expression Analysis ◽  
Tumor Suppressor Genes ◽  
Splice Variants ◽  
Suppressor Genes

scholarly journals Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0153902 ◽  
Author(s):  
Mariyam Zuberi ◽  
Imran Khan ◽  
Rashid Mir ◽  
Gauri Gandhi ◽  
Prakash Chandra Ray ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Tumor Suppressor ◽  
Epithelial Ovarian Cancer ◽  
Tumor Suppressor Genes ◽  
Prognostic Indicator ◽  
Suppressor Genes

scholarly journals BECN1 and BRCA1 Deficiency Sensitizes Ovarian Cancer to Platinum Therapy and Confers Better Prognosis

Biomedicines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 207
Author(s):  
Amreen Salwa ◽  
Alessandra Ferraresi ◽  
Menaka Chinthakindi ◽  
Letizia Vallino ◽  
Chiara Vidoni ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Tumor Suppressor ◽  
Cancer Patients ◽  
Tumor Suppressor Genes ◽  
Promoter Hypermethylation ◽  
Chromosome 17 ◽  
Loss Of Function ◽  
Suppressor Genes ◽  
Altered Expression ◽  
Platinum Based Chemotherapy

Background: BRCA1, BECN1 and TP53 are three tumor suppressor genes located on chromosome 17 and frequently found deleted, silenced, or mutated in many cancers. These genes are involved in autophagy, apoptosis, and drug resistance in ovarian cancer. Haploinsufficiency or loss-of-function of either TP53, BRCA1 or BECN1 correlates with enhanced predisposition to cancer development and progression, and chemoresistance. Expectedly, the combined altered expression of these three tumor suppressor genes worsens the prognosis of ovarian cancer patients. However, whether such a genotypic pattern indeed affects the chemo-responsiveness to standard chemotherapy thus worsening patients’ survival has not been validated in a large cohort of ovarian cancer patients. Aim: We interrogated datasets from the TCGA database to analyze how the expression of these three tumor suppressor genes impacts on the clinical response to platinum-based chemotherapy thus affecting the survival of ovarian cancer patients. Results and conclusion: Compared to EOC with homozygous expression of BECN1 and BRCA1, tumors expressing low mRNA expression of these two tumor suppressor genes (either because of shallow (monoallelic) co-deletion or of promoter hypermethylation), showed higher sensitivity to platinum-based therapies and were associated with a better prognosis of ovarian cancer-bearing patients. This outcome was independent of TP53 status, though it was statistically more significant in the cohort of patients with mutated TP53. Thus, sensitivity to platinum therapy (and probably to other chemotherapeutics) correlates with low expression of a combination of critical tumor suppressor genes. Our study highlights the importance of thoroughly assessing the genetic lesions of the most frequently mutated genes to stratify the patients in view of a personalized therapy. More importantly, the present findings suggest that targeting the function of both BECN1 and BRCA1 could be a strategy to restore chemosensitivity in refractory tumors.

Sign in / Sign up

Export Citation Format

Share Document